Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 58 of 58 entries
View as:

Docetaxel/Pemetrexed as 1st Line Treatment in Patients With Non Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT00684099 Org: User:
Start: 05/31/06 End: 05/31/09 Due: 05/31/10

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01985724 Org: User:
Start: 10/31/07 End: 12/31/13 Due: 12/31/14

Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01308086 Org: User:
Start: 10/31/10 End: 12/31/17 Due: 12/31/18

Postoperative Chemotherapy and Chemo-radiotherapy for Resected Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00718913 Org: User:
Start: 04/30/08 End: 09/30/09 Due: 09/30/10

Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00441740 Org: User:
Start: 04/30/04 End: 02/29/08 Due: 02/28/09

Pemetrexed Plus Bevacizumab in Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00741221 Org: User:
Start: 06/30/08 End: 10/31/16 Due: 10/31/17

Cabazitaxel in Relapsed and Metastatic NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT01852578 Org: User:
Start: 09/30/12 End: 08/31/13 Due: 08/31/14

Docetaxel Plus Bevacizumab in Metastatic Non Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00741195 Org: User:
Start: 04/30/08 End: 10/31/16 Due: 10/31/17